Page 191 - Veterinary Toxicology, Basic and Clinical Principles, 3rd Edition

158 SECTION | I General

VetBooks.ir it is possible to eliminate compounds that exhibit high will therefore be to continue monitoring and improving
the welfare of animals used in toxicity testing and to
levels of basal toxicity in several cell types and reduce
advise on issues relating to the development of in vitro
unnecessary suffering in animals. In both in vitro and
in vivo testing it is important to use a battery of appropri- alternatives.
ate endpoint measurements of both basal toxicity and cell/
tissue-specific toxicity at each level, in order to increase
the reliability and predictive potential of the data
produced. REFERENCES
In vitro toxicology has made significant advances in Arnold, D.L., Grice, H.C., Krewski, D.R., 1990. Handbook of In Vivo
the last few decades, by improving and finding solutions Toxicity Testing. Academic Press, San Diego, CA.
to its limitations. For example, cell culture systems are Auletta, C.S., 2004. Current in vivo assays for cutaneous toxicity: local
now being designed to be metabolically competent and and systemic toxicity testing. Pharmacol. Toxicol. 95, 201 208.
viable for several weeks, making them appropriate not Barlow, S.M., Greig, J.B., Bridges, J.W., et al., 2002. Hazard identifica-
only for short- but also for long-term toxicity testing tion by methods of animal-based toxicology. Food Chem. Toxicol.
40, 145 191.
(Bhogal et al., 2005). Extending this approach to a wider
Bhogal, N., Grindon, C., Combes, R., Balls, M., 2005. Toxicity testing:
range of cell culture systems will improve the prospect of
creating a revolution based on new technologies. Trends Biotechnol.
using in vitro methods for studying a wider range of
23, 299 307.
chronic toxicological phenomena. However, further devel-
Breier, J.M., Gassmann, K., Kayser, R., et al., 2010. Neural progeni-
opment and validation of in vitro models is required if tor cells as models for high-throughput screens of developmental
they are to be adopted on a much wider scale in order to neurotoxicity: state of the science. Neurotoxicol. Teratol. 32,
secure further reduction, replacement, and refinement of 4 15.
animal models. This will require further improvements in Buse, E., Habermann, G., Ostrburg, I., et al., 2003. Reproductive/devel-
cell culture technology and growth conditions, such as the opmental toxicity and immunotoxicity assessment in the nonhuman
increased use of hollow fiber systems to facilitate continu- primate model. Toxicology. 185, 221 227.
ous replenishment of media and supplements (Nussler Cocks, G., Romanyuk, N., Amemori, T., et al., 2013. Conditionally
immortalized stem cell lines from human spinal cord retain regional
et al., 2001). The increased use of microsomal activation
identity and generate functional interneurons and motor neurons.
systems and/or established cell lines transfected with
Stem Cell Res. Ther. 4, 69.
genes for mixed function oxidases is another approach
Cohen, J., Wilkin, G.P., 1996. Neural Cell Culture. A Practical
that will help to increase the metabolic competence of
Approach. Oxford University Press, Oxford.
in vitro models. Another promising in vitro approach Davila, J.C., Rodriguez, R.J., Melchert, R.B., Acosta Jr, D., 1998.
involves the use of adult or ESCs of human or rodent ori- Predictive value of in vitro model systems in toxicology. Annu. Rev.
gin. These cells can be either continuously cultured with- Pharmacol. Toxicol. 38, 63 96.
out being differentiated or they can generate a wide Davila, J.C., Cezar, G.G., Thiede, M., et al., 2004. Use and application
variety of functional mammalian cell types. In addition to of stem cells in toxicology. Toxicol. Sci. 79, 214 223.
its application in developmental toxicity testing, stem cell Davis, J., 2002. Basic Cell Culture. A Practical Approach. Oxford
technology has been successfully used to study mechan- University Press, Oxford.
deBlois, D., Horlick, R.A., 2001. Endotoxin sensitization to kinin B(1)
isms of toxicity and to screen new pharmaceutical com-
receptor agonist in non-human primate model: haemodynamic and
pounds for teratogenicity, genotoxicity, hepatotoxicity,
pro-inflammatory effects. Br. J. Pharmacol. 132, 327 335.
and cardiotoxicity (Davila et al., 1998, 2004).
Dhillon, V.S., Singh, J., Singh, H., Kler, R.S., 1995. In vitro and in vivo
The development of medium to high throughput meth-
genotoxicity of hormonal drugs. VI. Fluoxymesterone. Mutat. Res.
ods in proteomics, genomics, and metabolomics, together 342, 103 111.
with the revolution in bioinformatics, will lead to the Downs, T.R., Wilfinger, W.W., 1983. Fluorometric quantification of
accumulation of vast toxicological information, helping to DNA in cells and tissue. Anal. Biochem. 131, 538 547.
elucidate mechanisms of toxicity in both in vitro and Efthymiou, A., Shaltouki, A., Steiner, J.P., et al., 2014. Functional
in vivo models (Bhogal et al., 2005). These approaches screening assays with neurons generated from pluripotent stem cell-
will also help in the development and establishment of derived neural stem cells. J. Biomol. Screen. 19, 32 43.
new biomarkers of effect or exposure. EPA (Environmental Protection Agency), (1998a). Health Effects Test
Guidelines OPPTS 870.7200 Companion Animal Safety. EPA 712-
In conclusion, although it is a desirable goal to replace
C-98-349.
all animal testing, animal-based toxicological testing is
EPA (Environmental Protection Agency), (1998b). Health Effects Test
likely to continue for the foreseeable future. Further
Guidelines OPPTS 870.3700 Prenatal Developmental Toxicity
improvements in animal models will make them more reli-
Study. EPA 712-C-98-207.
able indicators of human toxicity, while the development EPA (Environmental Protection Agency), (1998c). Health Effects Test
of improved in vitro systems will eventually minimize the Guidelines OPPTS 870.5450 Rodent Dominant Lethal Assay. EPA
use of animals for toxicity studies. The veterinarian’s role 712-C-98-227.